MIMEDX GROUP, INC.

MiMedx Group, Inc. has entered into a definitive Merger Agreement with Sanara MedTech Inc., under which Sanara will become a wholly-owned subsidiary of MiMedx. Each outstanding share of Sanara common stock will be converted into $33.00 in cash and 0.4735 shares of MiMedx Common Stock. Both companies' Boards of Directors have unanimously approved the merger. The filing also corrects previously reported termination fees, clarifying that Sanara's fee is $9,660,336.00 and MiMedx's fee is $22,540,785.00.

MIMEDX Group, Inc. announced a definitive agreement to acquire Sanara MedTech Inc. for approximately $350 million in a cash and stock transaction, expected to close in 2026. This acquisition will be financed by a new $300 million senior secured term loan from Hayfin Capital Management LLP. For the second quarter of 2026, MIMEDX reported a net loss of $14.8 million, a significant decrease from a net income of $9.6 million in the prior year period. Net sales fell 34.7% to $64.4 million, primarily due to a 61.1% decline in Wound sales, though Surgical sales saw a 15.1% increase.

MIMEDX Group, Inc. announced plans to acquire Sanara MedTech for an enterprise value of approximately $350 million, with Sanara shareholders receiving $33.00 in cash and 0.4735 shares of MIMEDX common stock per share. Concurrently, MIMEDX reported its second quarter 2026 financial results, with net sales decreasing 35% year-over-year to $64 million, primarily due to a 61% decline in Wound sales impacted by Medicare reimbursement changes. Despite a 15% growth in Surgical product sales, the company posted a net loss of $15 million for the quarter. MIMEDX reiterated its full-year 2026 net sales guidance of $260-290 million, expecting to return to profitability in the second half of the year.

MIMEDX Group, Inc. announced a definitive merger agreement to acquire Sanara MedTech Inc. in a cash and stock transaction valued at approximately $350 million, or $35 per Sanara share. The acquisition aims to expand MIMEDX's surgical footprint, nearly doubling its surgical revenue, and is expected to be immediately accretive to revenue growth, gross margin, and Adjusted EBITDA margin. The combined entity anticipates over $20 million in run-rate cost synergies and expects 2027 total revenue to exceed $400 million with an Adjusted EBITDA margin over 20%. The company also announced its second quarter 2026 operating and financial results alongside this transaction.

MiMedx Group, Inc. held its 2026 Annual Meeting of Shareholders on June 10, 2026, where shareholders re-elected seven directors, approved an advisory resolution on executive compensation, and ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. Additionally, the Board of Directors approved an amendment to the company's bylaws, increasing the number of public company boards its chief executive officer may sit on to three.

MiMedx Group, Inc. announced that members of its senior management will attend the Craig-Hallum 23rd Annual Institutional Investor Conference. The event is scheduled for Thursday, May 28, 2026, in Minneapolis, MN. Investors wishing to meet with senior management are encouraged to contact their Craig-Hallum representative.

MIMEDX Group, Inc. announced the commercial launch of G4Derm Plus, an innovative 510(k)-cleared flowable biomimetic matrix for advanced wound management. The company secured exclusive U.S. distribution rights for this self-assembling peptide technology, expanding its portfolio for surgical markets. G4Derm Plus is now available through Premier and Vizient GPO agreements, facilitating a national launch and providing clinicians with a new solution for complex wounds.

MIMEDX GROUP, INC. (MDXG) will hold its 2026 Annual Meeting of Shareholders virtually on June 10, 2026, at 9:00 a.m. Eastern Time. Shareholders will vote on the election of seven directors, an advisory approval of executive compensation, and the ratification of Deloitte & Touche LLP as the independent auditor for fiscal year 2026. Two current directors, M. Kathleen Behrens and Cato T. Laurencin, are not standing for re-election, reducing the board size to seven members. The Board unanimously recommends voting for all proposals.

MIMEDX GROUP, INC. announced its 2026 Annual Meeting of Shareholders will be held virtually on June 10, 2026. Shareholders of record as of April 13, 2026, are invited to vote on the election of seven directors, an advisory resolution on executive compensation, and the ratification of Deloitte & Touche LLP as the independent auditor for fiscal year 2026. The Board will be reduced to seven members as two current directors are not seeking re-election.

MIMEDX Group reported a significant decline in Q1 2026, with net sales decreasing 33.1% to $59.0 million and a GAAP net loss of $(10.9) million, compared to a net income of $7.0 million in the prior year. This was primarily due to a 59.7% drop in Wound net sales following Medicare reimbursement changes, despite a 13.2% increase in Surgical net sales. The company also announced a cost reduction initiative, including a 15% workforce reduction, and launched new products while securing new distribution agreements.